Cannara Biotech Stock Today
| LOVFF Stock | USD 0.52 0.09 20.93% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Cannara Biotech is trading at 0.52 as of the 25th of November 2024. This is a 20.93 percent increase since the beginning of the trading day. The stock's lowest day price was 0.49. Cannara Biotech has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Cannara Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada. Cannara Biotech is traded on OTC Exchange in the United States.. The company has 877.48 M outstanding shares. More on Cannara Biotech
Moving together with Cannara OTC Stock
Moving against Cannara OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cannara OTC Stock Highlights
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Cannara Biotech [LOVFF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.27 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cannara Biotech's market, we take the total number of its shares issued and multiply it by Cannara Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cannara Biotech classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 877.48 M outstanding shares.
Cannara Biotech has accumulated about 3.88 M in cash with (6.08 M) of positive cash flow from operations.
Check Cannara Biotech Probability Of Bankruptcy
Ownership AllocationCannara Biotech holds a total of 877.48 Million outstanding shares. Cannara Biotech retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cannara Ownership Details
Cannara Biotech Risk Profiles
| Mean Deviation | 2.26 | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.32 | |||
| Risk Adjusted Performance | (0.03) |
Cannara Stock Against Markets
Picking the right benchmark for Cannara Biotech otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cannara Biotech otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cannara Biotech is critical whether you are bullish or bearish towards Cannara Biotech at a given time. Please also check how Cannara Biotech's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cannara Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Cannara Biotech Corporate Management
Elected by the shareholders, the Cannara Biotech's board of directors comprises two types of representatives: Cannara Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cannara. The board's role is to monitor Cannara Biotech's management team and ensure that shareholders' interests are well served. Cannara Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cannara Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Abitbol | VP Marketing | Profile | |
| France Landry | VP HR | Profile | |
| Zohar Krivorot | CEO Chairman | Profile | |
| Avi Krivorot | Chief Officer | Profile | |
| Anthony Manouk | VP GM | Profile | |
| Brian Sherman | G Affairs | Profile | |
| Julia Bouvet | Chief Staff | Profile |
Other Information on Investing in Cannara OTC Stock
Cannara Biotech financial ratios help investors to determine whether Cannara OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cannara with respect to the benefits of owning Cannara Biotech security.